Investors & Media

Investor Overview

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer.

domvanalimab

An Fc-silent anti-TIGIT antibody in Phase 2 and Phase 3 studies in non-small cell lung cancer in combination with zimberelimab and etrumadenant.

etrumadenant

A dual adenosine A2a/A2b receptor agonist being evaluated in Phase 1 and Phase 2 studies across multiple indications, including lung, colon and prostate cancer.

quemliclustat

A small molecule CD73 inhibitor in a randomized Phase 1 study for the treatment of metastatic pancreatic ductal adenocarcinoma.

zimberelimab

An anti-PD1 monoclonal antibody being studied in various combinations across the portfolio, including a Phase 3 study to support the potential approvals of both zimberelimab and zimberelimab plus domvanalimab.

AB308

an Fc-enabled anti-TIGIT antibody being studied in a Phase 1b trial with zimberelimab in people with advanced solid and hematologic malignancies.

AB521

A HIF-2alfa inhibitor currently in a Phase 1 study.

Latest Press Releases

Featured Presentation

Latest Events